Literature DB >> 21303343

Development of anti-viral agents using molecular modeling and virtual screening techniques.

Johannes Kirchmair1, Simona Distinto, Klaus Roman Liedl, Patrick Markt, Judith Maria Rollinger, Daniela Schuster, Gudrun Maria Spitzer, Gerhard Wolber.   

Abstract

Computational chemistry has always played a key role in anti-viral drug development. The challenges and the quickly rising public interest when a virus is becoming a threat has significantly influenced computational drug discovery. The most obvious example is anti-AIDS research, where HIV protease and reverse transcriptase have triggered enormous efforts in developing and improving computational methods. Methods applied to anti-viral research include (i) ligand-based approaches that rely on known active compounds to extrapolate biological activity, such as machine learning techniques or classical QSAR, (ii) structure-based methods that rely on an experimentally determined 3D structure of the targets, such as molecular docking or molecular dynamics, and (iii) universal approaches that can be applied in a structure- or ligand-based way, such as 3D QSAR or 3D pharmacophore elucidation. In this review we summarize these molecular modeling approaches as they were applied to fight anti-viral diseases and highlight their importance for anti-viral research. We discuss the role of computational chemistry in the development of small molecules as agents against HIV integrase, HIV-1 protease, HIV-1 reverse transcriptase, the influenza virus M2 channel protein, influenza virus neuraminidase, the SARS coronavirus main proteinase and spike protein, thymidine kinases of herpes viruses, hepatitis c virus proteins and other flaviviruses as well as human rhinovirus coat protein and proteases, and other picornaviridae. We highlight how computational approaches have helped in discovering anti-viral activities of natural products and give an overview on polypharmacology approaches that help to optimize drugs against several viruses or help to optimize the metabolic profile of and anti-viral drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303343     DOI: 10.2174/187152611794407782

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  17 in total

Review 1.  Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.

Authors:  Anna Egorova; Sean Ekins; Michaela Schmidtke; Vadim Makarov
Journal:  Eur J Med Chem       Date:  2019-06-11       Impact factor: 6.514

Review 2.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Assays for the identification of novel antivirals against bluetongue virus.

Authors:  Linlin Gu; Stewart W Schneller; Qianjun Li
Journal:  J Vis Exp       Date:  2013-10-11       Impact factor: 1.355

Review 4.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

5.  In Silico Drug Discovery for Treatment of Virus Diseases.

Authors:  Shikha Joon; Rajeev K Singla; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  PubChem3D: Diversity of shape.

Authors:  Evan E Bolton; Sunghwan Kim; Stephen H Bryant
Journal:  J Cheminform       Date:  2011-03-21       Impact factor: 5.514

Review 7.  Influenza neuraminidase.

Authors:  Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2011-11-16       Impact factor: 4.380

8.  Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine.

Authors:  Su-Sen Chang; Hung-Jin Huang; Calvin Yu-Chian Chen
Journal:  PLoS Comput Biol       Date:  2011-12-22       Impact factor: 4.475

Review 9.  Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.

Authors:  Lucianna Helene Santos; Rafaela Salgado Ferreira; Ernesto Raúl Caffarena
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

10.  Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.

Authors:  Pritam Kumar Panda; Murugan Natarajan Arul; Paritosh Patel; Suresh K Verma; Wei Luo; Horst-Günter Rubahn; Yogendra Kumar Mishra; Mrutyunjay Suar; Rajeev Ahuja
Journal:  Sci Adv       Date:  2020-07-10       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.